A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
Porphyrins with four methyl, two vinyl, and two propionic acid side chains attached to the pyrrole rings. Protoporphyrin IX occurs in hemoglobin, myoglobin, and most of the cytochromes.
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms.
An enzyme that catalyzes the formation of porphobilinogen from two molecules of 5-aminolevulinic acid. EC 4.2.1.24.
Therapy using oral or topical photosensitizing agents with subsequent exposure to light.
Keto acids that are derivatives of 4-oxopentanoic acids (levulinic acid).
An enzyme of the transferase class that catalyzes condensation of the succinyl group from succinyl coenzyme A with glycine to form delta-aminolevulinate. It is a pyridoxyal phosphate protein and the reaction occurs in mitochondria as the first step of the heme biosynthetic pathway. The enzyme is a key regulatory enzyme in heme biosynthesis. In liver feedback is inhibited by heme. EC 2.3.1.37.
Salts and esters of the 7-carbon saturated monocarboxylic acid heptanoic acid.
A hypnotic and sedative. Its use has been largely superseded by other drugs.
A group of compounds containing the porphin structure, four pyrrole rings connected by methine bridges in a cyclic configuration to which a variety of side chains are attached. The nature of the side chain is indicated by a prefix, as uroporphyrin, hematoporphyrin, etc. The porphyrins, in combination with iron, form the heme component in biologically significant compounds such as hemoglobin and myoglobin.
Porphobilinogen is a precursor molecule in the biosynthesis of heme, a vital component of hemoglobin and other proteins involved in oxygen transport.
An autosomal dominant porphyria that is due to a deficiency of HYDROXYMETHYLBILANE SYNTHASE in the LIVER, the third enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features are recurrent and life-threatening neurologic disturbances, ABDOMINAL PAIN, and elevated level of AMINOLEVULINIC ACID and PORPHOBILINOGEN in the urine.
An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)
Four PYRROLES joined by one-carbon units linking position 2 of one to position 5 of the next. The conjugated bond system results in PIGMENTATION.
The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.
The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis.
Oxidoreductases that are specific for ALDEHYDES.
Porphyrins with four acetic acid and four propionic acid side chains attached to the pyrrole rings.
Proteins found within the THYLAKOID MEMBRANES of photosynthetic organisms such as PLANTS and PHYTOPLANKTON. Many of the proteins in this class are involved in the process of PHOTOSYNTHESIS and the generation of ADENOSINE TRIPHOSPHATE.
A transfer RNA which is specific for carrying glutamic acid to sites on the ribosomes in preparation for protein synthesis.
A mitochondrial enzyme found in a wide variety of cells and tissues. It is the final enzyme in the 8-enzyme biosynthetic pathway of HEME. Ferrochelatase catalyzes ferrous insertion into protoporphyrin IX to form protoheme or heme. Deficiency in this enzyme results in ERYTHROPOIETIC PROTOPORPHYRIA.
Porphyrinogens which are intermediates in heme biosynthesis. They have four acetic acid and four propionic acid side chains attached to the pyrrole rings. Uroporphyrinogen I and III are formed from polypyrryl methane in the presence of uroporphyrinogen III cosynthetase and uroporphyrin I synthetase, respectively. They can yield uroporphyrins by autooxidation or coproporphyrinogens by decarboxylation.
Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Devices used in a technique by which cells or tissues are grown in vitro or, by implantation, in vivo within chambers permeable to diffusion of solutes across the chamber walls. The chambers are used for studies of drug effects, osmotic responses, cytogenic and immunologic phenomena, metabolism, etc., and include tissue cages.
An allylic compound that acts as a suicide inactivator of CYTOCHROME P450 by covalently binding to its heme moiety or surrounding protein.
Porphyrins which are combined with a metal ion. The metal is bound equally to all four nitrogen atoms of the pyrrole rings. They possess characteristic absorption spectra which can be utilized for identification or quantitative estimation of porphyrins and porphyrin-bound compounds.
Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.
Spherical phototrophic bacteria found in mud and stagnant water exposed to light.
Pyrrole containing pigments found in photosynthetic bacteria.
Enzymes of the isomerase class that catalyze the transfer of acyl-, phospho-, amino- or other groups from one position within a molecule to another. EC 5.4.
The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.
A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
Ethylenediamines are a class of organic compounds that are used in medicine as chelating agents to remove heavy metals from the body.
That portion of the electromagnetic spectrum in the visible, ultraviolet, and infrared range.
Esters are chemical compounds formed by the reaction of an alcohol and an acid, and they are commonly used in the medical field as drugs, solvents, and preservatives.
A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.19, symbol Pb. (Dorland, 28th)
Phenanthrolines are a class of organic compounds that have been used in the medical field as muscle relaxants and as components of some antibiotics.
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A cell line derived from cultured tumor cells.

Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval. (1/636)

We have studied different single and fractionated illumination schemes after systemic administration of 5-aminolevulinic acid (ALA) to Improve the response of nodular tumors to ALA-mediated photodynamic therapy. Tumors transplanted on the thigh of female WAG/Rij rats were transdermally illuminated with red light (633 nm) after systemic ALA administration (200 mg/kg). The effectiveness of each treatment scheme was determined from the tumor volume doubling time. A single illumination (100 J/cm2 at 100 mW/cm2, 2.5 h after ALA administration) yielded a doubling time of 6.6+/-1.2 days. This was significantly different from the untreated control (doubling time, 1.7+/-0.1 days). The only treatment scheme that yielded a significant improvement compared to all other schemes studied was illumination at both 1 and 2.5 h after ALA administration (both 100 J/cm2 at 100 mW/cm2) and resulted in a tumor volume doubling time of 18.9+/-2.9 days. A possible mechanism to explain this phenomenon is that the protoporphyrin IX formed after administration of ALA is photodegraded by the first illumination. In the 75-min interval, new porphyrin is formed enhancing the effect of the second illumination.  (+info)

Timing of illumination is essential for effective and safe photodynamic therapy: a study in the normal rat oesophagus. (2/636)

5-Aminolaevulinic acid (ALA)-induced, protoporphyrin IX (PpIX)-mediated photodynamic therapy (PDT) is an experimental treatment modality for (pre)malignant oesophageal lesions. This study aimed to optimize the time of illumination after ALA administration. Six groups of eight rats received 200 mg kg(-1) ALA orally, eight rats served as controls. Illumination was performed at 1, 2, 3, 4, 6 or 12 h after ALA administration with a 1-cm cylindrical diffuser placed in a balloon catheter (laser parameters: 633 nm, 25 J radiant energy, power output 100 mW). During illumination, fluorescence measurements and light dosimetry were performed. Animals were sacrificed at 48 h (n = 4) or 28 days (n = 4) after PDT. At day 28, an oesophagogram was performed. Largest PpIX fluorescence was found at 3 h after ALA administration. In vivo fluence rate was three times higher than the calculated incident fluence rate. At 48 h after PDT, major epithelial damage was found in all animals illuminated at 2 h, whereas less epithelial damage was found at 3-6 h and none at 1 and 12 h. In animals illuminated at 4, 6 and 12 h, but not at 2 h, oesophagograms showed severe dilatations and histology showed loss of Schwann cells. These results demonstrate that the choice of time interval between ALA administration and illumination is critical for achieving epithelial damage without oesophageal functional impairment. A short interval of 2-3 h seems to be most appropriate.  (+info)

Clinical spectral characterisation of colonic mucosal lesions using autofluorescence and delta aminolevulinic acid sensitisation. (3/636)

BACKGROUND AND AIMS: Laser induced fluorescence (LIF) from colonic mucosa was measured in vivo with and without delta aminolevulinic acid (ALA) in an attempt to differentiate between neoplasia and non-neoplasia in real time during colonoscopy. METHODS: Spectra from 32 adenomas, 68 normal sites, and 14 hyperplastic polyps in 41 patients were obtained with a point monitoring system. Twenty one of the patients had been given a low dose of ALA as a photosensitiser before the examination. Light of 337, 405, or 436 nm wavelength was used as excitation. Stepwise multivariate linear regression analysis was performed. RESULTS: With 337 nm excitation, 100% sensitivity and 96% specificity was obtained between normal mucosa and adenomas. Seventy seven per cent of the hyperplastic polyps were classified as non-neoplastic. When exciting with 405 and 436 nm, the possibility of distinguishing different types of tissue was considerably better in the ALA patients than in the non-ALA patients. CONCLUSIONS: The in vivo point measurements imply that a good discrimination between normal tissue and adenomatous polyps can be obtained using the LIF technique. Excitation at 337 nm and at 405 nm or 436 nm using ALA gives good results. LIF also shows potential for distinguishing adenomatous from hyperplastic polyps. The number of detection wavelengths could be reduced if chosen properly.  (+info)

Ultrastructural changes in PAM cells after photodynamic treatment with delta-aminolevulinic acid-induced porphyrins or photosan. (4/636)

Photodynamic therapy (PDT) is the combination of a photosensitizing drug (Ps) with light in the presence of oxygen leading to the generation of reactive molecular species and destruction of cancer cells. In this study we compared PDT with two Ps, the hematoporphyrin derivative Photosan (Ph) and delta-aminolevulinic acid (ALA)-induced endogenous protoporphyrin IX, with respect to mitochondrial function and ultrastructural alterations. The effects of PDT were investigated in PAM 212 cells after different Ps incubation times, light doses, and post-treatment periods. Both Ps induced a light dose-dependent impairment of the mitochondrial function with the dose-response curve being steep for ALA and flat for Ph. The prolongation of the incubation time from 4 to 20 h resulted in an increased reduction of mitochondrial activity after ALA PDT but not after Ph PDT. Treatment with an irradiation dose that decreased mitochondrial activity by 50% (IC50) led to early and profound changes of mitochondrial morphology in ALA photosensitized cells, whereas photosensitization with Ph resulted in more pronounced alterations of lysosomes. We conclude that at bioequivalent sublethal PDT exposures of PAM 212 cells, ALA-induced damage is primarily restricted to mitochondria, whereas Ph-induced cytotoxicity is mediated by damage of the lysosomal system.  (+info)

Role of heme in intracellular trafficking of thyroperoxidase and involvement of H2O2 generated at the apical surface of thyroid cells in autocatalytic covalent heme binding. (5/636)

Thyroperoxidase (TPO) is a glycosylated hemoprotein that plays a key role in thyroid hormone synthesis. We previously showed that in CHO cells expressing human TPO (hTPO) only 2% of synthesized hTPO reaches the cell surface. Herein, we investigated the role of heme moiety insertion in the exit of hTPO from the endoplasmic reticulum. Peroxidase activity at the cell surface and cell surface expression of hTPO were decreased by approximately 30 and approximately 80%, respectively, with succinyl acetone, an inhibitor of heme biosynthesis, and were increased by 20% with holotransferrin and aminolevulinic acid, precursors of heme biosynthesis. Results were similar with holotransferrin plus aminolevulinic acid or hemin, but hemin increased cell surface activity more efficiently (+120%) relative to the control. It had been suggested (DePillis, G., Ozaki, S., Kuo, J. M., Maltby, D. A., and Ortiz de Montellano, P. R. (1997) J. Biol. Chem. 272, 8857-8960) that covalent attachment of heme to mammalian peroxidases could be an H2O2-dependent autocatalytic processing. In our study, heme associated intracellularly with hTPO, and we hypothesized that there was insufficient exposure to H2O2 in Chinese hamster ovary cells before hTPO reached the cell surface. After a 10-min incubation, 10 microM H2O2 led to a 65% increase in cell surface activity. In contrast, in thyroid cells, H2O2 was synthesized at the apical cell surface and allowed covalent attachment of heme. Two-day incubation of primocultures of thyroid cells with catalase led to a 30% decrease in TPO activity at the cell surface. In conclusion, we provide compelling evidence for an essential role of 1) heme incorporation in the intracellular trafficking of hTPO and of 2) H2O2 generated at the apical pole of thyroid cells in the autocatalytic covalent heme binding to the TPO molecule.  (+info)

Hypoxia significantly reduces aminolaevulinic acid-induced protoporphyrin IX synthesis in EMT6 cells. (6/636)

We have studied the effects of hypoxia on aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) synthesis in EMT6 monolayer cultures characterized by different cell densities and proliferation rates. Specifically, after ALA incubation under hypoxic or normoxic conditions, we detected spectrofluorometrically the PpIX content of the following populations: (a) low-density exponentially growing cells; (b) high-density fed-plateau cells; and (c) high-density unfed-plateau cells. These populations were selected either for the purpose of comparison with other in vitro studies (low-density exponentially growing cells) or as representatives of tumour regions adjacent to (high-density fed-plateau cells) and further away from (high-density unfed-plateau cells) capillaries. The amount of PpIX per cell produced by each one of these populations was higher after normoxic ALA incubation. The magnitude of the effect of hypoxia on PpIX synthesis was dependent on cell density and proliferation rate. A 42-fold decrease in PpIX fluorescence was observed for the high-density unfed-plateau cells. PpIX production by the low-density exponential cells was affected the least by ALA incubation under hypoxic conditions (1.4-fold decrease), whereas the effect on the high-density fed-plateau population was intermediate (20-fold decrease).  (+info)

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. (7/636)

Photodynamic therapy with topically applied delta-aminolaevulinic acid is used to treat skin tumours by employing endogenously formed porphyrins as photosensitizers. This study examines the time course of porphyrin metabolite formation after topical application of delta-aminolaevulinic acid. Porphyrin biosynthesis in human skin tumours (basal cell carcinoma, squamous cell carcinoma), in psoriatic lesions, and in normal skin was investigated. Skin areas were treated with delta-aminolaevulinic acid, and levels of total porphyrins, porphyrin metabolites and proteins were measured in samples excised after 1, 2, 4, 6, 9, 12 and 24 h. There was an increase in porphyrin biosynthesis in all tissues with maximum porphyrin levels in tumours between 2 and 6 h and in psoriatic lesions 6 h after treatment. The pattern of porphyrins showed no significant difference between normal and neoplastic skin, protoporphyrin being the predominant metabolite. The results suggest that optimum irradiation time for superficial epithelial skin tumours may be as soon as 2 h after application of delta-aminolaevulinic acid, whereas for treatment of psoriatic lesions an application time of 6 h is more suitable.  (+info)

The iron regulatory protein can determine the effectiveness of 5-aminolevulinic acid in inducing protoporphyrin IX in human primary skin fibroblasts. (8/636)

The level of endogenous photosensitiser, protoporphyrin IX (PPIX), can be enhanced in the cells by 5-aminolevulinic acid (ALA). We investigated the effect of critical parameters such as growth state of the cells and availability of intracellular iron in modulating the level of PPIX, in human primary cultured skin fibroblasts (FEK4) maintained either in exponentially growing or growth-arrested phase, following treatment with ALA. The addition of ALA to exponentially growing cells increased the level of PPIX 6-fold relative to control cells; however, in growth-arrested cells the same treatment increased the level of PPIX up to 34-fold. The simultaneous addition of the hydrophilic iron-chelator Desferal with ALA, boosted the level of PPIX up to 47-fold in growing cells and up to 42-fold in growth-arrested cells, suggesting that iron is limiting under the latter conditions. The strict dependence of PPIX enhancement on free available iron levels was examined by the level of activation of iron regulatory protein in band shift assays. This analysis revealed that the basal level of iron regulatory protein in growth-arrested cells was 6-fold higher than in growing cells, reflecting the influence of the free available iron pool in exponentially growing cells. Interestingly, the same ratio was found between the basal level concentration of PPIX in growing and growth-arrested cells. We propose that iron regulatory protein activation could serve as a marker for developing photodynamic therapy protocols because it identifies cells and tissues with a propensity to accumulate PPIX and it is therefore likely to predict the effectiveness of such therapies.  (+info)

Aminolevulinic acid (ALA) is a naturally occurring amino acid that is involved in the biosynthesis of heme, a pigment found in hemoglobin, myoglobin, and other proteins. In the medical field, ALA is used as a photosensitizer in photodynamic therapy (PDT) for the treatment of various types of cancer, including skin cancer, lung cancer, and head and neck cancer. In PDT, a patient is given a topical application of a solution containing ALA, which is absorbed by the cancer cells. The ALA is then converted into protoporphyrin IX (PpIX), a highly fluorescent molecule that accumulates in the cancer cells. The patient is then exposed to a specific wavelength of light, which activates the PpIX and causes the destruction of the cancer cells. ALA is also used in the treatment of porphyria, a group of rare genetic disorders that affect the metabolism of heme. In porphyria, the accumulation of PpIX can cause symptoms such as abdominal pain, nausea, and vomiting. By inhibiting the production of PpIX, ALA can help to alleviate these symptoms and prevent the development of more severe complications.

Protoporphyrins are a group of pigments that are synthesized in the body as part of the heme biosynthesis pathway. Heme is a vital component of hemoglobin, which is responsible for carrying oxygen in red blood cells. Protoporphyrins are also found in other proteins, such as cytochromes, which are involved in cellular respiration. In the medical field, protoporphyrins are often measured in blood tests as a marker of iron metabolism. Elevated levels of protoporphyrins can indicate a deficiency in iron or other nutrients involved in heme synthesis, such as vitamin B12 or folate. On the other hand, low levels of protoporphyrins can be a sign of excessive iron stores or other medical conditions, such as liver disease or kidney failure. Protoporphyrins are also used as a diagnostic tool in the detection of certain types of cancer, such as bladder cancer and lung cancer. In these cases, elevated levels of protoporphyrins in the urine or blood can indicate the presence of cancer cells. Additionally, protoporphyrins have been studied as potential therapeutic agents for various diseases, including cancer, anemia, and neurological disorders.

Porphobilinogen synthase (also known as PBGS) is an enzyme that plays a crucial role in the biosynthesis of heme, a vital component of hemoglobin, myoglobin, and other heme-containing proteins. PBGS catalyzes the condensation of four molecules of 5-aminolevulinic acid (ALA) to form porphobilinogen (PBG), a precursor of heme. In the medical field, PBGS deficiency is a rare genetic disorder known as porphyria, which is characterized by the accumulation of toxic intermediates in the heme biosynthesis pathway. There are several types of porphyria, including acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP), which are caused by mutations in the PBGS gene. These mutations can result in reduced PBGS activity, leading to an accumulation of ALA and its toxic intermediates, which can cause symptoms such as abdominal pain, neurologic symptoms, and skin damage. In addition to its role in porphyria, PBGS is also a target for the development of new drugs for the treatment of other diseases, such as cancer and neurodegenerative disorders.

Levulinic acid is a naturally occurring organic compound that is produced during the metabolism of carbohydrates. It is a colorless, water-soluble liquid with a slightly acidic taste and a pungent odor. In the medical field, levulinic acid is used as a chemical intermediate in the production of various pharmaceuticals and other chemicals. It is also used as a solvent and a corrosion inhibitor. In addition, levulinic acid has been studied for its potential use in the treatment of certain types of cancer and other diseases.

5-Aminolevulinate synthetase is an enzyme that plays a crucial role in the biosynthesis of heme, a pigment found in red blood cells and other cells throughout the body. This enzyme catalyzes the conversion of glycine and succinyl-CoA to 5-aminolevulinic acid (ALA), which is the first and rate-limiting step in the heme biosynthetic pathway. In the medical field, 5-aminolevulinate synthetase is of particular interest because it is involved in the production of porphyrins, a group of pigments that are the building blocks of heme. Porphyrin metabolism disorders, such as porphyria, can result from mutations in the gene encoding 5-aminolevulinate synthetase or other enzymes in the heme biosynthetic pathway. These disorders can cause a range of symptoms, including abdominal pain, neurological problems, and skin sensitivity to light. In addition to its role in heme biosynthesis, 5-aminolevulinate synthetase has also been studied for its potential use in cancer therapy. ALA is a precursor to porphyrins, which can be converted to photodynamic therapy agents that can selectively kill cancer cells when exposed to light. This approach, known as photodynamic therapy, is being investigated as a treatment for various types of cancer, including skin cancer, lung cancer, and head and neck cancer.

In the medical field, "heptanoates" refers to a group of compounds that contain a heptanoic acid functional group. Heptanoic acid is a seven-carbon carboxylic acid, and its derivatives are known as heptanoates. Heptanoates are commonly used in the production of pharmaceuticals, cosmetics, and personal care products. They can also be used as intermediates in the synthesis of other compounds. In some cases, heptanoates may be used as a source of energy for the body. For example, heptanoic acid is a component of medium-chain triglycerides (MCTs), which are a type of dietary fat that can be easily metabolized by the body for energy. It is worth noting that the use of heptanoates in medicine and other fields is typically limited to specific applications and may require careful consideration of potential risks and side effects.

Glutethimide is a medication that was previously used to treat insomnia and other sleep disorders. It works by increasing the amount of a chemical in the brain called gamma-aminobutyric acid (GABA), which helps to calm the nervous system and promote sleep. However, glutethimide has been associated with serious side effects, including liver damage, mental health problems, and addiction. As a result, it is no longer widely used in the medical field and is only available in some countries as a prescription medication. If you are considering taking glutethimide or any other medication, it is important to talk to your doctor first to discuss the potential risks and benefits.

Porphyrins are a group of organic compounds that are essential for the production of hemoglobin, a protein found in red blood cells that carries oxygen throughout the body. Porphyrins are also involved in the metabolism of other substances, such as bile pigments and vitamin B12. In the medical field, porphyrins are often used as diagnostic tools for certain diseases. For example, elevated levels of porphyrins in the blood or urine can be a sign of liver disease, kidney disease, or anemia. Porphyrins can also accumulate in the skin and other tissues in conditions such as porphyria, a group of rare genetic disorders that affect the metabolism of porphyrins. In addition, porphyrins have been studied for their potential therapeutic applications. Some porphyrins have been shown to have anti-cancer properties, while others have been used to treat certain types of infections and to deliver drugs to specific cells in the body.

Porphobilinogen (PBG) is a chemical compound that is an intermediate in the biosynthesis of heme, a vital component of hemoglobin, myoglobin, and other heme proteins. PBG is synthesized from glycine and succinyl-CoA in a series of enzymatic reactions that take place in the liver and other tissues. In the medical field, PBG is often measured in the blood as part of a diagnostic test for porphyria, a group of rare genetic disorders that affect the metabolism of heme. Elevated levels of PBG in the blood can be an indicator of porphyria, which can cause a range of symptoms including abdominal pain, skin sensitivity to sunlight, and neurological problems.

Porphyria, Acute Intermittent (AI) is a rare genetic disorder that affects the body's ability to produce heme, a protein that carries oxygen in red blood cells. This disorder is caused by a deficiency in the enzyme porphobilinogen deaminase, which is necessary for the production of heme. The symptoms of Porphyria, Acute Intermittent can vary widely and may include abdominal pain, nausea, vomiting, constipation, muscle weakness, numbness or tingling in the extremities, and sensitivity to light (photophobia). In severe cases, the disorder can lead to seizures, confusion, and even coma. Porphyria, Acute Intermittent is inherited in an autosomal dominant pattern, which means that an affected individual has a 50% chance of passing the disorder on to each of their children. There is currently no cure for Porphyria, Acute Intermittent, but treatment can help manage symptoms and prevent complications. This may include medications to relieve pain and nausea, as well as measures to prevent exposure to triggers such as alcohol, certain medications, and stress.

Melanoma, amelanotic is a type of melanoma (a type of skin cancer) that lacks the pigment (melanin) that gives most melanomas their characteristic black or brown color. This type of melanoma is usually pink, red, white, or light brown in color, which can make it more difficult to detect. Amelanotic melanoma is less common than other types of melanoma, but it is more aggressive and tends to spread more quickly to other parts of the body. It is important to have any unusual or changing moles checked by a dermatologist to detect melanoma early, when it is most treatable.

Tetrapyrroles are a class of organic compounds that contain four pyrrole rings connected by methine bridges. They are important in the field of medicine because they are the building blocks of several important biological molecules, including heme, chlorophyll, and vitamin B12. Heme is a tetrapyrrole that is a key component of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. Chlorophyll is a tetrapyrrole that is essential for photosynthesis, the process by which plants convert sunlight into energy. Vitamin B12 is a tetrapyrrole that is important for the proper functioning of the nervous system and the production of red blood cells. Tetrapyrroles can also be used as drugs to treat a variety of conditions. For example, heme is used to treat a type of anemia called hemolytic anemia, in which the body destroys red blood cells too quickly. Chlorophyll derivatives have been used to treat certain types of cancer, and vitamin B12 is used to treat vitamin B12 deficiency, which can cause anemia, nerve damage, and other problems.

Heme is a complex organic molecule that contains iron and is a vital component of hemoglobin, myoglobin, and other proteins involved in oxygen transport and storage in living organisms. It is also a component of various enzymes involved in metabolism and detoxification processes. In the medical field, heme is often used as a diagnostic tool to detect and monitor certain medical conditions, such as anemia (a deficiency of red blood cells or hemoglobin), liver disease (which can affect heme synthesis), and certain types of cancer (which can produce abnormal heme molecules). Heme is also used in the production of certain medications, such as heme-based oxygen carriers for use in patients with sickle cell disease or other conditions that affect oxygen transport. Additionally, heme is a component of some dietary supplements and is sometimes used to treat certain types of anemia.

Aldehyde oxidoreductases (ALDHs) are a group of enzymes that play a crucial role in the metabolism of aldehydes, which are toxic compounds that can be produced during normal cellular metabolism or as a result of environmental exposure. ALDHs are found in many tissues throughout the body, including the liver, lungs, and kidneys, and they help to detoxify aldehydes by converting them into less toxic compounds. There are several different types of ALDHs, each with its own specific substrate and activity. Some ALDHs are involved in the metabolism of ethanol, while others are involved in the metabolism of other aldehydes, such as acetaldehyde, formaldehyde, and acrolein. ALDHs are also involved in the metabolism of certain drugs and toxins, and they have been implicated in the development of certain diseases, such as cancer and neurodegenerative disorders. In the medical field, ALDHs are often studied as potential targets for the development of new drugs and therapies. For example, drugs that inhibit ALDH activity have been shown to be effective in the treatment of certain types of cancer, and ALDHs are also being studied as potential biomarkers for the early detection of certain diseases. Additionally, ALDHs are being investigated as potential targets for the development of new therapies for the treatment of alcoholism and other addictions.

Uroporphyrins are a group of porphyrin compounds that are formed during the heme biosynthesis pathway. They are precursors to heme, which is a vital component of hemoglobin, myoglobin, and other heme proteins that play important roles in oxygen transport and storage in the body. Uroporphyrins are synthesized in the liver and kidneys and are excreted in the urine. Abnormal levels of uroporphyrins in the urine can be an indication of certain medical conditions, such as porphyria, a group of rare genetic disorders that affect the metabolism of porphyrins. In addition to their role in heme biosynthesis, uroporphyrins have also been studied for their potential therapeutic applications. For example, some uroporphyrins have been shown to have anti-cancer properties and are being investigated as potential treatments for various types of cancer.

Thylakoid membrane proteins are a group of proteins that are found in the thylakoid membranes of chloroplasts. These proteins play a crucial role in the process of photosynthesis, which is the process by which plants, algae, and some bacteria convert light energy into chemical energy in the form of glucose. There are several different types of thylakoid membrane proteins, including light-harvesting proteins, reaction center proteins, and ATP synthase. Light-harvesting proteins are responsible for capturing light energy and transferring it to the reaction center proteins, where it is used to power the process of photosynthesis. ATP synthase is responsible for generating ATP, which is the energy currency of the cell. Thylakoid membrane proteins are essential for the proper functioning of photosynthesis, and mutations in these proteins can lead to a variety of problems, including reduced photosynthetic efficiency and impaired growth and development.

RNA, Transfer, Glu refers to a specific type of transfer RNA (tRNA) molecule that carries the amino acid glutamic acid (Glu) during protein synthesis in cells. Transfer RNAs are small RNA molecules that recognize specific sequences of messenger RNA (mRNA) and bring the corresponding amino acid to the ribosome, where it is incorporated into a growing polypeptide chain. RNA, Transfer, Glu is one of the 20 different types of tRNA molecules that are involved in protein synthesis in cells. Each tRNA molecule is specific to a particular amino acid and has a unique sequence of nucleotides that allows it to recognize and bind to the corresponding sequence of mRNA. The process of protein synthesis involves the coordinated action of many different types of RNA molecules, including mRNA, tRNA, and ribosomal RNA (rRNA), as well as various enzymes and other proteins.

Ferrochelatase is an enzyme that plays a crucial role in the metabolism of iron in the human body. It is responsible for inserting iron into the heme molecule, which is a component of hemoglobin, myoglobin, and other proteins that transport oxygen in the body. Ferrochelatase is encoded by the HFE gene, which is located on chromosome 6. Mutations in the HFE gene can lead to a condition called hereditary hemochromatosis, which is characterized by an excessive accumulation of iron in the body. This can lead to a range of health problems, including liver damage, heart disease, and diabetes. In addition to its role in iron metabolism, ferrochelatase has also been implicated in the regulation of iron homeostasis and the response to oxidative stress. It is a potential target for the development of new treatments for iron overload disorders and other conditions related to iron metabolism.

Uroporphyrinogens are a group of molecules that are precursors to heme, a vital component of hemoglobin, myoglobin, and other proteins involved in oxygen transport in the body. They are synthesized in the liver from the amino acid glycine and a series of other precursors, including porphobilinogen. There are four different uroporphyrinogens, each of which is numbered according to the position of the first pyrrole ring in the porphyrin ring structure. Uroporphyrinogen I, II, III, and IV are synthesized in a stepwise manner, with each subsequent step involving the addition of a pyrrole ring to the growing porphyrin ring structure. Uroporphyrinogens are important for the production of heme, which is necessary for the proper functioning of red blood cells and other cells that require oxygen transport. Deficiencies in the enzymes involved in the synthesis of uroporphyrinogens can lead to a variety of disorders, including porphyria, a group of rare genetic disorders characterized by the accumulation of toxic porphyrin intermediates in the body.

Erythema is a redness or discoloration of the skin that is caused by an increase in blood flow to the affected area. It can be caused by a variety of factors, including inflammation, infection, allergies, exposure to sunlight or other environmental irritants, and certain medications. Erythema can be a sign of a more serious underlying condition, such as a skin infection or an allergic reaction, and it is important to seek medical attention if it is accompanied by other symptoms or if it does not resolve on its own.

Deferoxamine is a medication used to treat iron overload, a condition in which there is too much iron in the body. It works by binding to iron in the blood and removing it from the body through the kidneys. Deferoxamine is typically administered as an intravenous infusion and is used to treat conditions such as thalassemia, sickle cell anemia, and hemochromatosis. It may also be used to prevent iron overload in people who receive frequent blood transfusions. Deferoxamine can cause side effects such as nausea, vomiting, and low blood pressure.

Allylisopropylacetamide (also known as acetamide allyl isopropyl ether or 2-(allyloxy)acetamide) is a chemical compound that has been used in the medical field as an anticonvulsant and anesthetic. It is a white, crystalline solid that is soluble in water and organic solvents. In the past, allylisopropylacetamide was used to treat seizures and other neurological disorders, but its use has been largely discontinued due to concerns about its toxicity and potential for adverse side effects. It is not currently approved for use in humans by any regulatory agency. In the laboratory, allylisopropylacetamide is used as a solvent and as a starting material for the synthesis of other compounds. It has also been studied for its potential as a fungicide and as a corrosion inhibitor.

Metalloporphyrins are a class of compounds that consist of a porphyrin ring with a metal ion (such as iron, cobalt, or manganese) at its center. They are often used in the medical field as a diagnostic tool for certain diseases, such as anemia, and as a treatment for others, such as certain types of cancer. Metalloporphyrins are also being studied for their potential use in the development of new drugs and therapies.

Chlorophyll is a green pigment found in plants, algae, and some bacteria. It plays a crucial role in photosynthesis, the process by which plants convert light energy into chemical energy to fuel their growth and metabolism. In the medical field, chlorophyll has been studied for its potential health benefits. Some research suggests that chlorophyll may have antioxidant properties, which could help protect against damage from free radicals and reduce the risk of chronic diseases such as cancer and heart disease. Chlorophyll has also been studied for its potential to support liver health, improve digestion, and boost energy levels. However, more research is needed to fully understand the potential health benefits of chlorophyll, and it is not currently used as a medical treatment. It is typically consumed as a dietary supplement or found in foods that are rich in chlorophyll, such as leafy green vegetables, broccoli, and parsley.

Bacteriochlorophylls are pigments found in certain bacteria that are similar in structure to chlorophyll, the pigment found in plants and algae that is responsible for photosynthesis. Bacteriochlorophylls are used by bacteria to convert light energy into chemical energy, which they use to fuel their metabolic processes. They are typically found in bacteria that live in environments that are low in light, such as deep sea vents or the soil. Bacteriochlorophylls are important for the study of bacterial metabolism and have potential applications in the development of new technologies for energy production and biotechnology.

Intramolecular transferases are a class of enzymes that catalyze the transfer of a functional group within a single molecule, without the involvement of a coenzyme or a second substrate. These enzymes are involved in various metabolic pathways and play important roles in the synthesis and breakdown of biomolecules such as carbohydrates, lipids, and nucleotides. Examples of intramolecular transferases include: * Transketolase: This enzyme catalyzes the transfer of a ketone group from one sugar molecule to another, as part of the pentose phosphate pathway. * Transaldolase: This enzyme catalyzes the transfer of an aldehyde group from one sugar molecule to another, as part of the same pathway. * Phosphoglycerate mutase: This enzyme catalyzes the transfer of a phosphate group within a molecule of 3-phosphoglycerate, as part of the glycolytic pathway. * Glycogen phosphorylase: This enzyme catalyzes the transfer of a phosphate group from ATP to a molecule of glycogen, as part of the breakdown of glycogen. Intramolecular transferases are important in the regulation of metabolic pathways and the maintenance of cellular homeostasis. They are also involved in the synthesis of important biomolecules such as nucleotides and amino acids.

Succinic acid is a naturally occurring dicarboxylic acid that is found in many plants and animals. It is also produced industrially as a precursor to other chemicals, such as polyester and nylon. In the medical field, succinic acid is used as a metabolic intermediate in the citric acid cycle, which is a series of chemical reactions that occur in the mitochondria of cells to produce energy. It is also used as a medication to treat certain types of metabolic disorders, such as lactic acidosis, which is a condition characterized by an excess of lactic acid in the blood. Succinic acid is also used as a food additive, as a flavoring agent, and as a preservative. It is generally considered safe for consumption in small amounts, but larger amounts can be harmful and may cause symptoms such as nausea, vomiting, and diarrhea.

Ethylenediamines are a class of organic compounds that contain two amine groups (-NH2) bonded to a central carbon atom through an ethylene (-CH2-CH2-) bridge. They are commonly used as starting materials for the synthesis of various chemicals and polymers, including polyurethanes, dyes, and pharmaceuticals. In the medical field, ethylenediamines are used as intermediates in the synthesis of various drugs and as corrosion inhibitors in medical equipment. They have also been studied for their potential anti-inflammatory and anti-cancer properties. One specific ethylenediamine, called diethylenetriamine (DETA), has been used as an antifungal agent in the treatment of fungal infections, particularly in immunocompromised patients. However, its use is limited due to its potential toxicity and side effects. Overall, ethylenediamines are an important class of compounds with a wide range of applications in the medical field, but their use must be carefully monitored to minimize potential risks and side effects.

In the medical field, esters are chemical compounds that are formed by the reaction of an alcohol and an acid. They are commonly used in medicine as drugs, solvents, and intermediates in the synthesis of other compounds. One example of an ester used in medicine is acetylsalicylic acid, also known as aspirin. Aspirin is an ester of salicylic acid and acetic acid, and it is used as a pain reliever, anti-inflammatory, and anticoagulant. Esters can also be used as carriers for drugs, allowing them to be more easily absorbed into the body. For example, ethyl acetate is often used as a solvent for drugs that are not soluble in water, and it can also be used as a carrier for drugs that are not well absorbed through the digestive system. Overall, esters play an important role in the medical field, and their properties and uses continue to be studied and explored by researchers.

In the medical field, "lead" can refer to several different things, including: 1. Lead poisoning: A condition caused by exposure to high levels of lead, which can damage the brain, kidneys, and other organs. Lead poisoning can occur through ingestion of lead-contaminated food or water, inhalation of lead dust or fumes, or absorption through the skin. 2. Lead shield: A protective covering made of lead or lead alloy used to shield patients and medical personnel from ionizing radiation during medical imaging procedures such as X-rays or CT scans. 3. Lead apron: A protective garment worn by medical personnel during procedures involving ionizing radiation to shield the body from exposure to harmful levels of radiation. 4. Lead acetate: A medication used to treat lead poisoning by binding to lead ions in the body and preventing them from being absorbed into the bloodstream. 5. Lead poisoning test: A medical test used to diagnose lead poisoning by measuring the level of lead in the blood or urine.

Phenanthrolines are a class of organic compounds that are commonly used as chelating agents in the medical field. They are particularly useful in the treatment of heavy metal poisoning, as they can bind to the metal ions and help to remove them from the body. Phenanthrolines are also used as antioxidants and anti-inflammatory agents, and have been studied for their potential use in the treatment of a variety of conditions, including cancer, cardiovascular disease, and neurological disorders. One of the most well-known phenanthrolines is procaine, which is a local anesthetic used in dentistry and other medical procedures. Other phenanthrolines that are used in medicine include hydralazine, which is used to treat high blood pressure, and amantadine, which is used to treat Parkinson's disease and influenza. Overall, phenanthrolines are a versatile class of compounds with a wide range of potential medical applications.

Glycine is an amino acid that is essential for the proper functioning of the human body. It is a non-essential amino acid, meaning that the body can synthesize it from other compounds, but it is still important for various physiological processes. In the medical field, glycine is used as a dietary supplement to support muscle growth and recovery, as well as to improve sleep quality. It is also used in the treatment of certain medical conditions, such as liver disease, as it can help to reduce the buildup of toxins in the liver. Glycine is also used in the production of various medications, including antibiotics and tranquilizers. It has been shown to have a calming effect on the nervous system and may be used to treat anxiety and other mental health conditions. Overall, glycine is an important nutrient that plays a vital role in many physiological processes in the body.

Glioblastoma is a type of brain tumor that is classified as a grade IV astrocytoma, which means it is a highly aggressive and rapidly growing cancer. It is the most common and deadly type of primary brain tumor in adults, accounting for about 15% of all brain tumors. Glioblastoma typically arises from the supportive cells of the brain called astrocytes, but it can also develop from other types of brain cells. The tumor is characterized by its ability to infiltrate and spread into the surrounding brain tissue, making it difficult to remove completely through surgery. Symptoms of glioblastoma can vary depending on the location of the tumor in the brain, but common symptoms include headaches, seizures, nausea, vomiting, memory loss, and changes in personality or behavior. Treatment for glioblastoma typically involves a combination of surgery, radiation therapy, and chemotherapy. Despite these treatments, glioblastoma is generally considered to be incurable, with a median survival rate of about 15 months from diagnosis.

Brain neoplasms, also known as brain tumors, are abnormal growths of cells in the brain. They can be either benign (non-cancerous) or malignant (cancerous). Brain tumors can occur in any part of the brain and can be primary (originating from brain cells) or secondary (spreading from other parts of the body to the brain). Symptoms of brain neoplasms can vary depending on the location and size of the tumor, but may include headaches, seizures, changes in vision or hearing, difficulty with balance or coordination, and changes in personality or behavior. Diagnosis of brain neoplasms typically involves a combination of imaging tests such as MRI or CT scans, as well as a biopsy to confirm the presence of cancer cells. Treatment options for brain neoplasms may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. The specific treatment plan will depend on the type, location, and stage of the tumor, as well as the overall health of the patient.

Glioma is a type of brain tumor that arises from the glial cells, which are the supportive cells of the brain and spinal cord. Gliomas are the most common type of primary brain tumor, accounting for about 80% of all brain tumors. They can occur in any part of the brain, but are most commonly found in the frontal and temporal lobes. Gliomas are classified based on their degree of malignancy, with grades I to IV indicating increasing levels of aggressiveness. Grade I gliomas are slow-growing and have a better prognosis, while grade IV gliomas are highly aggressive and have a poor prognosis. Symptoms of gliomas can vary depending on the location and size of the tumor, but may include headaches, seizures, changes in vision or speech, difficulty with coordination or balance, and personality changes. Treatment options for gliomas may include surgery, radiation therapy, chemotherapy, and targeted therapy, depending on the type and stage of the tumor.

Astrocytoma is a type of brain tumor that arises from astrocytes, which are star-shaped cells that support and nourish neurons in the brain. Astrocytomas are the most common type of primary brain tumor, accounting for about 30% of all brain tumors. They can occur at any age, but are most common in adults between the ages of 40 and 60. Astrocytomas are classified into four grades based on their degree of malignancy and ability to invade surrounding tissues. Grade I astrocytomas are slow-growing and low-grade, while grade IV astrocytomas are highly aggressive and fast-growing. Treatment options for astrocytomas depend on the grade of the tumor, the location of the tumor in the brain, and the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, and targeted therapy.

Dacarbazine (DTIC-DMA) is a chemotherapy drug that is used to treat various types of cancer, including melanoma (a type of skin cancer), Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It works by interfering with the growth and division of cancer cells, which can slow down or stop the growth of tumors. Dacarbazine is usually given intravenously (into a vein) or as an injection under the skin. It can cause side effects such as nausea, vomiting, hair loss, and low blood cell counts.

δ-Aminolevulinic acid (also dALA, δ-ALA, 5ALA or 5-aminolevulinic acid), an endogenous non-proteinogenic amino acid, is the ... Aminolevulinic acid is being studied for photodynamic therapy (PDT) in a number of types of cancer. It is not currently a first ... Aminolevulinic acid is indicated in adults for visualization of malignant tissue during surgery for malignant glioma (World ... "Aminolevulinic acid". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Articles with short ...
... (ALA synthase, ALAS, or delta-aminolevulinic acid synthase) is an enzyme (EC 2.3.1.37) that ... Aminolevulinic Acid Synthase Deficiency results in a lack of ability to create heme since its job is to catalyze the first step ... Beale, S I (June 1978). "δ-Aminolevulinic Acid in Plants: Its Biosynthesis, Regulation, and Role in Plastid Development". ... The reaction is as follows: succinyl-CoA + glycine ⇌ {\displaystyle \rightleftharpoons } δ-aminolevulinic acid + CoA + CO2 This ...
Aminolevulinic acid dehydratase (porphobilinogen synthase, or ALA dehydratase, or aminolevulinate dehydratase) is an enzyme (EC ... It catalyzes the following reaction, the second step of the biosynthesis of porphyrin: 2 5-Aminolevulinic acid ⇌ {\displaystyle ... synthesizes porphobilinogen through the asymmetric condensation of two molecules of aminolevulinic acid. All natural ...
... (also known as "Doss porphyria", "plumboporphyria", or "ADP") is an ... These biomarkers include urine porphobilinogen (PBG), aminolevulinic acid (ALA), and porphyrins found in blood and urine. PBG ... deficiency results in the accumulation of a toxic metabolic precursor in the heme synthesis pathway called aminolevulinic acid ... autosomal recessive metabolic disorder that results from inappropriately low levels of the enzyme delta-aminolevulinic acid ...
On the Role of Bacteroid delta-Aminolevulinic Acid Synthase and delta-Aminolevulinic Acid Dehydrase in the Synthesis of the ... Kaczor CM, Smith MW, Sangwan I, O'Brian MR (April 1994). "Plant delta-aminolevulinic acid dehydratase. Expression in soybean ... Sangwan I, O'Brian MR (March 1992). "Characterization of delta-Aminolevulinic Acid Formation in Soybean Root Nodules". Plant ... Heme groups are the same in all known leghemoglobins, but the amino acid sequence of the globin differs slightly depending on ...
... is an aminolevulinic acid synthase. Delta-aminolevulinate synthase catalyzes the condensation of glycine with succinyl- ... CoA to form delta-aminolevulinic acid. This nuclear-encoded mitochondrial enzyme is the first and rate-limiting enzyme in the ...
... is an aminolevulinic acid synthase. The product of this gene specifies an erythroid-specific mitochondrially located ...
... delta-aminolevulinic acid, and schizophrenia". Environmental Health Perspectives. 112 (5): 548-552. doi:10.1289/ehp.6777. PMC ... Drugs such as ketamine, PCP (angel dust), and LSD ("acid"), have been used to mimic schizophrenia for research purposes. Using ...
... and a γ-amino acid has it on the third. Examples include β-alanine, GABA, and δ-aminolevulinic acid. β-alanine: an amino acid ... ic acid.) Most natural amino acids are α-amino acids in the L conformation, but some exceptions exist. Some non-α-amino acids ... γ-Aminobutyric acid (GABA): a neurotransmitter in animals. δ-Aminolevulinic acid: an intermediate in tetrapyrrole biosynthesis ... Chemically synthesized amino acids can be called unnatural amino acids. Unnatural amino acids can be synthetically prepared ...
The initial steps incorporate glutamic acid into 5-aminolevulinic acid (ALA); two molecules of ALA are then reduced to ... diphosphate This forms an ester of the carboxylic acid group in chlorophyllide b with the 20-carbon diterpene alcohol phytol. ...
It is isomerized by glutamate-1-semialdehyde 2,1-aminomutase to give aminolevulinic acid in the biosynthesis of porphyrins, ... Glutamate-5-semialdehyde Beale SI (August 1990). "Biosynthesis of the Tetrapyrrole Pigment Precursor, delta-Aminolevulinic Acid ... Gamma-Amino acids, All stub articles, Biochemistry stubs). ...
Givosiran is an siRNA that breaks down aminolevulinic acid synthase 1 (ALAS1) mRNA in the liver. Breaking down ALAS1 mRNA ... Bissell, DM; Lai, JC; Meister, RK; Blanc, PD (2015). "Role of delta-aminolevulinic acid in the symptoms of acute porphyria". ... such as aminolevulinic acid (ALA) and porphobilinogen (PBG) from accumulating. To facilitate entry into the cytoplasm, ... Qiu S, Adema CM, Lane T (2005). "A computational study of off-target effects of RNA interference". Nucleic Acids Research. 33 ( ...
15 September 2006). "Lead and δ-Aminolevulinic Acid Dehydratase Polymorphism: Where Does It Lead? A Meta-Analysis". ... For example, the creation of the hydronium (H3O+) ion occurs when acids are dissolved in water and is due to the oxygen atom ... They are also referred to in the chemistry of Lewis acids and bases. However, not all non-bonding pairs of electrons are ...
The initial steps incorporate glutamic acid into 5-aminolevulinic acid (ALA); two molecules of ALA are then reduced to ... diphosphate This forms an ester of the carboxylic acid group in chlorophyllide a with the 20-carbon diterpene alcohol phytol. ...
... such as aminolevulinic acid, which may be directly or indirectly harmful to neurons. Elevation of aminolevulinic acid results ... Scinicariello F, Murray HE, Moffett DB, Abadin HG, Sexton MJ, Fowler BA (January 2007). "Lead and delta-aminolevulinic acid ... for the pathology of lead is that it interferes with the activity of an essential enzyme called delta-aminolevulinic acid ... such as found in facilities that process lead-acid batteries or produce lead wire or pipes, metal recycling and foundries, and ...
Common dehydratases include: Delta-aminolevulinic acid dehydratase is found in blood and is involved in the production of the ... "Improved Method for Measurement of delta-Aminolevulinic Acid DehydrataseActivity of Human Erythrocytes". Clinical Chemistry. 17 ... Induction and Repression of Serine Dehydratase and Phosphoglycerate Dehydrogenase by Proteins and Dietary-Essential Amino Acids ...
Neumann J, Brandsch M (2003). "Delta-aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct". J. ...
Elevation of aminolevulinic acid from lead-induced disruption of heme synthesis results in lead poisoning having symptoms ... Acute intermittent porphyria (AIP), variegate porphyria (VP), aminolevulinic acid dehydratase deficiency porphyria (ALAD) and ... Modification of the Mauzerall-Granick method for the determination of urinary aminolevulinic acid]". Orvosi Hetilap (in ...
"Isolation and biochemical characterization of delta-aminolevulinic acid dehydratase from Streptomyces yokosukanensis ATCC 25520 ... "Isolation and biochemical characterization of delta-aminolevulinic acid dehydratase from Streptomyces yokosukanensis ATCC 25520 ...
December 2015). "Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery". ... "Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre ... initial removal of the tumor may be increased if the surgery is guided by a fluorescent dye known as 5-aminolevulinic acid. GBM ...
"Effect of aluminum on δ-aminolevulinic acid dehydratase (ALA-D) and the development of cucumber (Cucumis sativus)". ... This allows aluminium to be used to store reagents such as nitric acid, concentrated sulfuric acid, and some organic acids. In ... Van Ginkel, M.F.; Van Der Voet, G.B.; D'haese, P.C.; De Broe, M.E.; De Wolff, F.A. (1993). "Effect of citric acid and maltol on ... They are hard acids and react readily with ligands, forming adducts. In industry, they are mostly used in alkene insertion ...
An important biomarker assay for lead poisoning is δ-aminolevulinic acid levels in plasma, serum, and urine. By the mid-1980s, ... Organic acids, such as acetic acid, dissolve lead in the presence of oxygen. Concentrated alkalis will dissolve lead and form ... Lead metal resists sulfuric and phosphoric acid but not hydrochloric or nitric acid; the outcome depends on insolubility and ... See for details on how a lead-acid battery works. Rates vary greatly by country. An alloy of brass (copper and zinc) with lead ...
"Identification of a novel iron-responsive element in murine and human erythroid delta-aminolevulinic acid synthase mRNA". The ... Nucleic Acids Research. 38 (Web Server): W360-W367. doi:10.1093/nar/gkq371. ISSN 0305-1048. PMC 2896125. PMID 20460462. Khan, M ... Nucleic Acids Research. 38 (Web Server issue): W360-W367. doi:10.1093/nar/gkq371. ISSN 0305-1048. PMC 2896125. PMID 20460462. R ... Nucleic Acids Research. 42 (10): 6567-6577. doi:10.1093/nar/gku248. ISSN 0305-1048. PMC 4041422. PMID 24728987. T. S. Huang; O ...
Acute intermittent porphyria Aminolevulinic acid Inborn error of metabolism "HAEM ARGINATE FOR THE ACUTE ATTACK OF PORPHYRIA". ... It is given intravenously, and its action of mechanism is to reduce the overproduction of δ-aminolevulinic acid, which can ...
... and aminolevulinic acid. GT198 has protein sequence homology with DNA topoisomerase, so that DNA topoisomerase inhibitors are ... GT198 is a small protein with its monomer contains 217 amino acids. It comprises a DNA-binding domain and forms a protein ...
"Study of mutations in aminolevulinic acid dehydratase (ALAD) gene in cattle from fly ash zone in Maharashtra, India." Indian ...
An ALA (delta-aminolevulinic acid) test is used to test for the presence of porphyrin and cytochrome compounds. Finding hemin ... Mycolic acid is a fatty acid found in the disease tuberculosis, offering a chemical target for diagnosticians to look for. With ... Deaminase is the enzyme that can deaminate the amino acid phenylalanine into the products ammonia and phenylpyruvic acid. The ... Mycolic acid analysis has been an evolving field of study for gas-liquid chromatography, as it offers a solution to slow growth ...
"Constitutive expression of RyhB regulates the heme biosynthesis pathway and increases the 5-aminolevulinic acid accumulation in ... These include two other genes encoding enzymes in the tricarboxylic acid cycle, acnA and fumA, two ferritin genes, ftnA and bfr ... Oglesby AG, Murphy ER, Iyer VR, Payne SM (December 2005). "Fur regulates acid resistance in Shigella flexneri via RyhB and ydeP ... 2006). "Target prediction for small, noncoding RNAs in bacteria". Nucleic Acids Research. 34 (9): 2791-2802. doi:10.1093/nar/ ...
Examples include aminolevulinic acid (ALA), Silicon Phthalocyanine Pc 4, m-tetrahydroxyphenylchlorin (mTHPC) and mono-L- ... They can interact with cellular components including unsaturated lipids, amino acid residues and nucleic acids. If sufficient ... the inner two pyrrolenine nitrogens can be protonated with acids such as trifluoroacetic acid affording a dicationic ... 5-Aminolaevulinic acid (ALA) is a prodrug used to treat and image multiple superficial cancers and tumours. ALA a key precursor ...
For instance, succinylacetone has been shown to decrease heme concentrations by inhibiting δ-aminolevulinic acid in murine ... For example, one pathway may be responsible for the synthesis of a particular amino acid, but the breakdown of that amino acid ... The tricarboxylic acid cycle (TCA) and glutaminolysis can also be targeted for cancer treatment, since they are essential for ... The glyoxylate shunt pathway is an alternative to the tricarboxylic acid (TCA) cycle, for it redirects the pathway of TCA to ...
Aminolevulinic Acid Topical: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before using aminolevulinic acid,. *tell your doctor and pharmacist if you are allergic to aminolevulinic acid, porphyrins, or ... Aminolevulinic acid is in a class of medications called photosensitizing agents. When aminolevulinic acid is activated by light ... Aminolevulinic acid may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *tingling, ...
Aminolevulinic Acid Hydrochloride Gel) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews ... No data are available regarding the presence of aminolevulinic acid in human milk, the effects of aminolevulinic acid on the ... Each gram of AMELUZ gel, 10% contains 100 mg of aminolevulinic acid hydrochloride (equivalent to 78 mg of aminolevulinic acid). ... Each gram of AMELUZ contains 100 mg of aminolevulinic acid hydrochloride (equivalent to 78 mg aminolevulinic acid) as the ...
LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.. Questions? Call our customer API support number 1-(800)-881-8210. ...
5-aminolevulinic acid. * August 15, 2020 Intraoperative MRI Versus 5-ALA in High-Grade Glioma Resection: A Network Meta- ... 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of ...
Porphobilinogen and aminolevulinic acid may be normal when the patient is not exhibiting symptoms.. ... Plasma porphobilinogen (PBG) and aminolevulinic acid (ALA) are elevated during the symptomatic phase of the acute porphyrias: ... Plasma porphobilinogen (PBG) and aminolevulinic acid (ALA) are elevated during the symptomatic phase of the acute porphyrias: ... Plasma porphobilinogen (PBG) and aminolevulinic acid (ALA) are elevated during the acute phase of these neurologic porphyrias. ...
Aminolevulinic acid dehydratase (ALAD) deficiency and acute intermittent porphyria (AIP) cause predominately neurovisceral ... With the exception of aminolevulinic acid dehydratase (ALAD) deficiency, acute porphyrias can be diagnosed during acute ... in which attacks are caused by induction of the enzyme 5-aminolevulinic acid synthase 1 (ALAS1). Givosiran is a small ... an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1, in Acute Hepatic Porphyria Patients. 2019 Apr 13 ...
AIMS: To assess the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for treatment of LS.. METHODS: ... The Efficacy and Safety of 5-Aminolevulinic Acid Photodynamic Therapy for Lichen Sclerosus: A Meta Analysis.. Chun Qing, ...
... aminolevulinic acid HCL) + BLU-U®, a prescription treatment for minimally to moderately thick actinic keratosis, trusted for ...
5-Aminolevulinic acid (also dALA, 5-ALA, 5ALA or 5-aminolevulinic acid), an endogenous non-protein amino acid, is the first ... 5-Aminolevulinic Acid Hydrochloride Market Growth 2019-2024 Abstract: This report studies the 5-Aminolevulinic Acid ... Benzenesulfonic Acid (CAS 98-11-3) Market Research Report 2018 Abstract: This report studies the global Benzenesulfonic Acid ( ... This report studies the global Ethyl Ascorbic Acid market status and forecast, categorizes the global Ethyl Ascorbic Acid ...
Aminolevulinic Acid. *Belladonna. *Belladonna Alkaloids. *Betel Nut. *Evening Primrose. *Midodrine. *Phenylalanine. ...
... than 5-aminolevulinic acid (ALA)-PDT (mycological cure rates of 17 %-57 %) and methyl aminolevulinate (MAL)-PDT (mycological ...
5-Aminolevulinic Acid for Fluorescence-Guided Resection and Treatment of Brain Tumors: Current Approaches. ...
5-aminolevulinic acid (ALA) is a precursor of tetrapyrroles and plays a vital role in plant stress adaptation. ALA improved the ... FA: Tridecanoic acid, heptadecanoic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, arachidic acid, ... FA: palmitic acid and stearic acid. OM: Citric acid, fumaric acid, malic acid and phosphoric acid. [59]. ... FA: Palmitic acid. OM: Citric acid, α-ketoglutaric acid, fumaric acid, malic acid, succinic acid, glucosan, menthol, 4- ...
Topical Phototherapy and Aminolevulinic Acid (ALA). Topical phototherapy with the drug aminolevulinic acid (ALA) is a ... However, certain substances in the skin, particularly a chemical called urocanic acid, can suppress such immune factors when ... Other topical agents under investigation include resiquimod, piroxicam, dobesilate, and betulinic acid. ...
5-Aminolevulinic acid (5-ALA) is useful as a photodynamic agent, but its use commonly leads to hypotension. Although avoiding a ... 5-Aminolevulinic acid (5-ALA) is a natural amino acid that is a precursor of protoporphyrin IX (Pp IX), which is a ... 5-Aminolevulinic acid (5-ALA) is useful as a photodynamic agent, but its use commonly leads to hypotension. Although avoiding a ... ALA, 5-aminolevulinic acid; OR, operating room; BP1, blood pressure before 5-ALA intake; BP2, blood pressure when entering ...
... find details about 5-Aminolevulinic Acid Hydrochloride manufacturer manufacturers, supplier and wholesaler - ZHENYIBIO. ... 5-Aminolevulinic Acid Hydrochloride manufacturer on sale manufacturers, ...
Pitfalls in preparation of 3H-unconjugated bilirubin by biosynthetic labeling from precursor 3H-5-aminolevulinic acid in the ...
... using 5-aminolevulinic acid (5-ALA) is a skin cancer therapy that still has limitations due to the low penetration of this drug ... MA L, Moan J, Peng Q, Iani V: Production of protoporphyrin IX induced by 5-aminolevulinic acid in transplanted human ... Oishi H, Nomiyama H, Nomiyama K, Tomokuni K: Fluorometric HPLC determination of 5-aminolevulinic acid (ALA) in the plasma and ... Lopez RFV, Bentley MVLB, Delgado-Charro MB, Guy RH: Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. ...
5-ALA; 5-aminolevulinic acid; EV; IFC; PpIX; extracellular vesicles; glioblastoma; imaging flow cytometry; liquid biopsy; nano- ... We used 5-aminolevulinic acid (5-ALA) to induce release of endogenously fluorescent tumour-specific EVs (EVPpIX ). Analysis of ... Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid Glioblastoma-derived extracellular ... vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications. Hsia, Tiffaney; Yekula, Anudeep ...
Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015 Mar. 128 (3):313-7. [QxMD MEDLINE Link]. [ ... Aminolevulinic acid dehydratase (ALAD) deficiency porphyria, also known as Doss porphyria, is extremely rare. [14] Abdominal ... The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis. 2004. 27( ... Test for increased 5-aminolevulinic acid and porphobilinogen (PBG) in a single-void urine collected during an attack. ...
Photodynamic therapy, using topically applied 5-aminolevulinic acid as the sensitizing agent for 635 nm laser light, has also ... Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer 85 (5): 649-53, 2000. [ ... Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol 80 (1 ...
Aminolevulinic Acid: (Minor) Corticosteroids administered prior to or concomitantly with photosensitizing agents used in ... Hemin: (Moderate) Hemin works by inhibiting aminolevulinic acid synthetase. Corticosteroids increase the activity of this ... Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Moderate) Monitor for gastrointestinal toxicity during concurrent ... Benzoic Acid; Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate: (Moderate) Monitor for gastrointestinal toxicity ...
... such as aminolevulinic acid, which may be directly or indirectly harmful to neurons.[191] Elevation of aminolevulinic acid ... "Lead and delta-aminolevulinic acid dehydratase polymorphism: where does it lead? A meta-analysis". Environmental Health ... Battery recycling workers are at risk for lead exposure.[103] This worker ladles molten lead into billets in a lead-acid ... for the pathology of lead is that it interferes with the activity of an essential enzyme called delta-aminolevulinic acid ...
Kinetics of 5-Aminolevulinic Acid-Induced Fluorescence in Organ Cultures of Bronchial Epithelium and Tumor Respiration ( ...
aminolevulinic acid oral. Serious - Use Alternative (1)aminolevulinic acid oral, tetracycline. Either increases toxicity of the ... aminolevulinic acid topical. Serious - Use Alternative (1)tetracycline increases toxicity of aminolevulinic acid topical by ... aminolevulinic acid oral. aminolevulinic acid oral, tetracycline. Either increases toxicity of the other by pharmacodynamic ... aminolevulinic acid topical. tetracycline increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid ...
An important biomarker assay for lead poisoning is δ-aminolevulinic acid levels in plasma, serum, and urine.[274] ... Lead metal resists sulfuric and phosphoric acid but not hydrochloric or nitric acid; the outcome depends on solubility and ... The reactions in the battery between lead, lead dioxide, and sulfuric acid provide a reliable source of voltage.[r] The lead in ... Its weak metallic character is illustrated by its amphoteric nature; lead and its oxides react with acids and bases, and it ...
Delta -aminolevulinic acid dehydratase (ALAD) plays an important role in lead poisoning, and polymorphisms in the ALAD gene ... These genes are delta-aminolevulinic acid dehydratase (ALAD) gene, the hemochromatosis gene and the vitamin D receptor (VDR). ... Lead toxicity symptoms arise are thought to occur by interfering with an essential enzyme delta-AminoLevulinic Acid Dehydratase ... "Lead and delta-aminolevulinic acid dehydratase polymorphism: where does it lead? A meta-analysis". Environ Health Perspect. 115 ...
5-aminolevulinic acid *brimonidine: postmarketing *furosemide *ketoconazole *mafenide acetate *malvidin: postmarketing * ...
  • The Efficacy and Safety of 5-Aminolevulinic Acid Photodynamic Therapy for Lichen Sclerosus: A Meta Analysis. (qxmd.com)
  • To assess the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for treatment of LS. (qxmd.com)
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) is a skin cancer therapy that still has limitations due to the low penetration of this drug into the skin. (biomedcentral.com)
  • Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. (bvsalud.org)
  • PDT approach More recently, a photodynamic therapy (PDT) approach using topical 5-aminolevulinic acid 20 percent (5-ALA, Levulan Kerastick, Dusa) applied for a 30 minute to 60 minute contact period followed by irradiation with a pulsed dye laser, intense pulsed light source, or blue or red light source has been investigated for treating acne. (dermatologytimes.com)
  • The topical application of 5-aminolevulinic acid (5-ALA) followed by light irradiation is a new concept of PDT [ 2 ]. (biomedcentral.com)
  • tell your doctor and pharmacist if you are allergic to aminolevulinic acid, porphyrins, or any other medications. (medlineplus.gov)
  • Consistent with this hypothesis is our finding that on the conversion of porphobilinogen to porphyrins, either by heating under acid conditions or by enzymatic conversion in cell-free extracts, formaldehyde i, formed. (nationalacademies.org)
  • When aminolevulinic acid is activated by light, it damages the cells of actinic keratosis lesions. (medlineplus.gov)
  • 5-aminolevulinic acid (5-ALA) and its metabolite protoporphyrin IX (PpIX) show anti-inflammatory and antiviral effects for Zika, Dengue, influenza A viruses, and SARS-CoV-2. (asploro.com)
  • Increases in erythrocyte delta-aminolevulinic-acid-dehydratase and zinc-protoporphyrin following lead (7439921) exposure were mentioned as examples of biomarkers of exposure. (cdc.gov)
  • 1. The relationship of the tricarboxylic acid cycle and porphyrin formation. (nationalacademies.org)
  • CROSS technique (Chemical Reconstruction Of Skin Scars) with tricarboxylic acid (TCA) is a local (applied only to the scar) treatment that is useful for pitted scars. (medderm.net)
  • Aminolevulinic acid is in a class of medications called photosensitizing agents. (medlineplus.gov)
  • Two mole cules of aminolevulinic acid are condensed through the action porphobilinogen synthase to form porphobilinogen. (others-signal.com)
  • For example, if you have aminolevulinic acid applied in the late afternoon, you will need to have the blue light treatment the next morning. (medlineplus.gov)
  • Your doctor will examine you 8 weeks after aminolevulinic acid and PDT treatment to decide whether you need retreatment of the same skin area. (medlineplus.gov)
  • If you become pregnant during treatment with aminolevulinic acid, call your doctor. (medlineplus.gov)
  • If you cannot return to the doctor for blue light treatment 14 to 18 hours after levulinic acid application, call your doctor. (medlineplus.gov)
  • Aminolevulinic acid comes in a special applicator to be made into a solution and applied to the affected skin area by a doctor. (medlineplus.gov)
  • you should know that aminolevulinic acid will make your skin very sensitive to sunlight (likely to get sunburn). (medlineplus.gov)
  • Use of other skin products while using azelaic acid gel might trigger extra inflammation. (lowescouponn.com)
  • It may be worth noting that azaserine has no inhibitory effect on the conversion of b-aminolevulinic acid to heme. (nationalacademies.org)
  • A portion of amino acids 480-530 of human ALAS-1 was used as the immunogen. (lsbio.com)
  • This is not a checklist of all drugs or health issue that interact with aminolevulinic acid gel. (lowescouponn.com)
  • You must return to the doctor 14 to 18 hours after aminolevulinic acid application to be treated by blue light PDT. (medlineplus.gov)
  • Your doctor will probably tell you not to use aminolevulinic acid. (medlineplus.gov)
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are using aminolevulinic acid. (medlineplus.gov)
  • Call your doctor right now if your bronchial asthma becomes worse while you use azelaic acid gel. (lowescouponn.com)
  • Within the anaerobic branch, 7 archaeal enzymes are acknowledged to be concerned from the conversion of precorrin 2 into cobyrinic acid, but two pathway gaps nonetheless continue to be. (others-signal.com)
  • A set of eleven genes is acknowledged for being involved in conversion of cobyrinic acid into adenosylco balamin. (others-signal.com)
  • magadii was incapable of de novo cobalamin biosyn thesis considering that it lacked the genes encoding enzymes for conversion of precorrin 2 into cobyrinic acid. (others-signal.com)
  • magadii also contained a set of genes that have been predicted to get involved in the conversion of cobyrinic acid into adenosylcobalamin, like a gene that's certain for the archaeal corrinoid salvage pathway. (others-signal.com)
  • Aminolevulinic acid-induced photodynamic therapy has been used successfully to treat various skin lesions of the nipple. (nih.gov)
  • Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF-200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials. (nih.gov)
  • Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. (nih.gov)
  • Comparison of efficiency of photodynamic diagnostics with topical use of the 3% and 15% aminolevulinic acid in the detection of vulvar lesions. (nih.gov)
  • Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA), a precursor to the potent photosensitizer, protoporphyrin IX (PpIX), is an established modality for several malignant and premalignant diseases. (nih.gov)
  • Although various photodynamic therapy photosensitizers have been studied in dermatology, this article focuses on the uses of topically applied aminolevulinic acid (ALA) and methylaminolevulinate (MAL). (medscape.com)
  • Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. (bvsalud.org)
  • To confirm the reproducibility of the effectiveness and safety in photodynamic diagnosis of non-muscle-invasive bladder cancer using 5- aminolevulinic acid in a prospective multicenter non-randomized phase III trial. (bvsalud.org)
  • These findings confirm the diagnostic efficacy and safety of photodynamic diagnosis with 20 mg/kg of oral 5- aminolevulinic acid , and show that transurethral resection of bladder tumors with a fluorescent light source using oral 5- aminolevulinic acid is well tolerated. (bvsalud.org)
  • Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application. (jamanetwork.com)
  • Improved response of plaque psoriasis after multiple treatments with topical 5-aminolevulinic acid photodynamic therapy. (jamanetwork.com)
  • Photodynamic therapy with 5-aminolevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. (jamanetwork.com)
  • Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. (jamanetwork.com)
  • Prenatal lead exposure, delta-aminolevulinic acid, and schizophrenia. (nih.gov)
  • Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen. (nih.gov)
  • Although each of these conditions has characteristic urine biochemistry, all exhibit excess delta-aminolevulinic acid. (nih.gov)
  • Delta-aminolevulinic acid in a water-in-oil emulsion was applied to the lesions and irradiation was performed. (who.int)
  • PDT employs a photosensitizing medication called the Levulan® Kerastick® (aminolevulinic acid) and application of a light source, typically blue light . (medage.com)
  • Analysis of blood for amino-levulinic acid dehydratase, albumin, glucose, hemoglobin, osmolality, packed cell volume, total protein, triglycerides, and uric acid failed to reveal any differences among groups that would indicate physiological impairment related to contaminants. (usgs.gov)
  • 2. Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma. (nih.gov)
  • 3. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. (nih.gov)
  • 4. Endoscopic-assisted visualization of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery: a technical note. (nih.gov)
  • 6. 5-Aminolevulinic acid fluorescence guided resection of malignant glioma: Hong Kong experience. (nih.gov)
  • 10. Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). (nih.gov)
  • 11. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. (nih.gov)
  • 18. 5-Aminolevulinic Acid: Pitfalls of Fluorescence-guided Resection for Malignant Gliomas and Application for Malignant Glioma Therapy. (nih.gov)
  • Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. (nih.gov)
  • 8. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. (nih.gov)
  • 5- Aminolevulinic acid (20 mg/kg) was orally administered 3 h before transurethral resection of bladder tumors using white light or fluorescent light . (bvsalud.org)
  • Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. (cysview.com)
  • When aminolevulinic acid is activated by light, it damages the cells of actinic keratosis lesions. (medlineplus.gov)
  • Aminolevulinic acid comes in a special applicator to be made into a solution and applied to the affected skin area by a doctor. (medlineplus.gov)
  • 1. Fluorescence-guided resection of primary and recurrent malignant gliomas with 5-aminolevulinic acid. (nih.gov)
  • 5. Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients. (nih.gov)
  • 9. Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation. (nih.gov)
  • 17. Enhanced resection of primary high-grade gliomas using a combination of intraoperative magnetic resonance imaging and intraoperative fluorescence (5-aminolevulinic acid): A single-centre experience. (nih.gov)
  • 19. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. (nih.gov)
  • The metabolism of aminolevulinic acid ( ALA) is the first step in the biochemical pathway resulting in heme synthesis. (nih.gov)
  • Arginine and Proline metabolism midobutanoic acid, cis-4-hydroxy- documented effects reported are from epidemiological studies in adult humans the formula. (nih.gov)
  • 12. Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas. (nih.gov)
  • We report the results of cloning genes for two key biosynthetic enzymes of different 5-aminolevulinic acid (ALA) biosynthetic routes from Streptomyces. (unipr.it)
  • You must return to the doctor 14 to 18 hours after aminolevulinic acid application to be treated by blue light PDT. (medlineplus.gov)
  • If you cannot return to the doctor for blue light treatment 14 to 18 hours after levulinic acid application, call your doctor. (medlineplus.gov)
  • Hypotension and urticaria were severe adverse events whose relationship to oral 5- aminolevulinic acid could not be excluded. (bvsalud.org)
  • Delta-ALA is a protein (amino acid ) produced by the liver. (nih.gov)
  • For example, if you have aminolevulinic acid applied in the late afternoon, you will need to have the blue light treatment the next morning. (medlineplus.gov)
  • No information is available on the use of oral aminolevulinic acid during breastfeeding. (nih.gov)
  • 5- Aminolevulinic acid synthase: mechanism, mutations and medicine. (nih.gov)
  • Aminolevulinic acid may cause side effects. (medlineplus.gov)
  • Webber JKessel DFromm D Side effects and photosensitization of human tissues after aminolevulinic acid. (jamanetwork.com)
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are using aminolevulinic acid. (medlineplus.gov)
  • Do not put a dressing or bandage on the area treated with aminolevulinic acid. (medlineplus.gov)